{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:34:10Z","timestamp":1773794050223,"version":"3.50.1"},"reference-count":114,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.idc.2025.12.004","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T21:19:28Z","timestamp":1769030368000},"page":"183-203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current Management of Serious Infections due to Vancomycin-resistant Enterococci"],"prefix":"10.1016","volume":"40","author":[{"given":"Sara I.","family":"Gomez-Villegas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William R.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar A.","family":"Arias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10325","key":"10.1016\/j.idc.2025.12.004_bib1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Antimicrobial Resistance","year":"2022","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.idc.2025.12.004_bib2","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa1914433","article-title":"Multidrug-resistant bacterial infections in U.S. hospitalized patients, 2012-2017","volume":"382","author":"Jernigan","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.idc.2025.12.004_bib3","series-title":"WHO bacterial priority pathogens list, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance","year":"2024"},{"key":"10.1016\/j.idc.2025.12.004_bib4","series-title":"Services USDoHaH","article-title":"COVID-19 U.S. impact on antimicrobial resistance, special report 2022","year":"2022"},{"issue":"4","key":"10.1016\/j.idc.2025.12.004_bib5","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/nrmicro2761","article-title":"The rise of the enterococcus: beyond vancomycin resistance","volume":"10","author":"Arias","year":"2012","journal-title":"Nat Rev Microbiol"},{"issue":"10","key":"10.1016\/j.idc.2025.12.004_bib6","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2310852121","article-title":"Global diversity of enterococci and description of 18 previously unknown species","volume":"121","author":"Schwartzman","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.idc.2025.12.004_bib7","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s41579-024-01054-w","article-title":"ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics","volume":"22","author":"Miller","year":"2024","journal-title":"Nat Rev Microbiol"},{"issue":"3","key":"10.1016\/j.idc.2025.12.004_bib8","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab616","article-title":"Contemporary clinical and molecular epidemiology of vancomycin-resistant enterococcal bacteremia: a prospective multicenter cohort study (VENOUS I)","volume":"9","author":"Contreras","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2025.12.004_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00058-18","article-title":"The enterococcus: a model of adaptability to its environment","volume":"32","author":"Garcia-Solache","year":"2019","journal-title":"Clin Microbiol Rev"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2025.12.004_bib10","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1086\/491711","article-title":"Vancomycin resistance in gram-positive cocci","volume":"42","author":"Courvalin","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2025.12.004_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/ice.2019.296","article-title":"Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: summary of data reported to the National Healthcare Safety Network, 2015-2017","volume":"41","author":"Weiner-Lastinger","year":"2020","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"5","key":"10.1016\/j.idc.2025.12.004_bib12","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.chom.2019.03.008","article-title":"Intestinal bile acids induce a morphotype switch in vancomycin-resistant enterococcus that facilitates intestinal colonization","volume":"25","author":"McKenney","year":"2019","journal-title":"Cell Host Microbe"},{"issue":"7771","key":"10.1016\/j.idc.2025.12.004_bib13","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41586-019-1501-z","article-title":"Microbiota-derived lantibiotic restores resistance against vancomycin-resistant enterococcus","volume":"572","author":"Kim","year":"2019","journal-title":"Nature"},{"issue":"7214","key":"10.1016\/j.idc.2025.12.004_bib14","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/nature07250","article-title":"Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits","volume":"455","author":"Brandl","year":"2008","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.idc.2025.12.004_bib15","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1086\/650203","article-title":"Bacterial flagellin stimulates toll-like receptor 5-dependent defense against vancomycin-resistant enterococcus infection","volume":"201","author":"Kinnebrew","year":"2010","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2025.12.004_bib16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00000658-200102000-00016","article-title":"Surveillance strategies and impact of vancomycin-resistant enterococcal colonization and infection in critically ill patients","volume":"233","author":"Hendrix","year":"2001","journal-title":"Ann Surg"},{"issue":"12","key":"10.1016\/j.idc.2025.12.004_bib17","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1172\/JCI43918","article-title":"Vancomycin-resistant enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans","volume":"120","author":"Ubeda","year":"2010","journal-title":"J Clin Investig"},{"issue":"1","key":"10.1016\/j.idc.2025.12.004_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw246","article-title":"Colonization with vancomycin-resistant enterococci and risk for bloodstream infection among patients with malignancy: a systematic review and meta-analysis","volume":"4","author":"Alevizakos","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2025.12.004_bib19","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/j.1600-6143.2008.02304.x","article-title":"Outcomes of colonization with MRSA and VRE among liver transplant candidates and recipients","volume":"8","author":"Russell","year":"2008","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.idc.2025.12.004_bib20","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1086\/502196","article-title":"Effect of nosocomial vancomycin-resistant enterococcal bacteremia on mortality, length of stay, and costs","volume":"24","author":"Song","year":"2003","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.idc.2025.12.004_bib21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jhin.2023.09.008","article-title":"Epidemiology and outcomes of vancomycin-resistant enterococcus infections: a systematic review and meta-analysis","volume":"141","author":"Eichel","year":"2023","journal-title":"J Hosp Infect"},{"issue":"1","key":"10.1016\/j.idc.2025.12.004_bib22","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2024.2309969","article-title":"Comparison of morbidity and mortality after bloodstream infection with vancomycin-resistant versus -susceptible enterococcus faecium: a nationwide cohort study in Denmark, 2010-2019","volume":"13","author":"Bager","year":"2024","journal-title":"Emerg Microb Infect"},{"issue":"1","key":"10.1016\/j.idc.2025.12.004_bib23","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciad612","article-title":"State-of-the-Art review: persistent enterococcal bacteremia","volume":"78","author":"Rogers","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2025.12.004_bib24","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1186\/s12879-022-07864-8","article-title":"Risk factors and outcomes associated with persistent vancomycin resistant enterococcal bacteremia","volume":"22","author":"Fox","year":"2022","journal-title":"BMC Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2025.12.004_bib25","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1093\/jac\/dkaf197","article-title":"Enterococcus faecium bacteraemia: a multicentre observational study focused on risk factors for clinical and microbiological outcomes","volume":"80","author":"Rinaldi","year":"2025","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.idc.2025.12.004_bib26","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jacc.2019.11.047","article-title":"A contemporary picture of enterococcal endocarditis","volume":"75","author":"Pericas","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.idc.2025.12.004_bib27","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/cid\/ciz1177","article-title":"Long-term outcome of patients with nonoperated prosthetic valve infective endocarditis: is relapse the main issue?","volume":"71","author":"Lecomte","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2025.12.004_bib28","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/cid\/ciac777","article-title":"Impact of Enterococcus faecalis endocarditis treatment on risk of relapse","volume":"76","author":"Danneels","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2025.12.004_bib29","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1093\/cid\/ciac953","article-title":"Therapeutic issues in relapsing Enterococcus faecalis endocarditis","volume":"76","author":"Cuervo","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2025.12.004_bib30","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/cid\/ciac956","article-title":"Reply to Cuervo et al and Horinouchi et al","volume":"76","author":"Danneels","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2025.12.004_bib31","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1093\/infdis\/jiaf358","article-title":"Clinical and genomic characterization of recalcitrant enterococcal bacteremia: a multicenter prospective cohort study (VENOUS)","volume":"232","author":"Simar","year":"2025","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2025.12.004_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02124-16","article-title":"RelA mutant Enterococcus faecium with multiantibiotic tolerance arising in an immunocompromised host","volume":"8","author":"Honsa","year":"2017","journal-title":"mBio"},{"issue":"3","key":"10.1016\/j.idc.2025.12.004_bib33","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01083-23","article-title":"C-terminal deletion of RelA protein is suggested as a possible cause of infective endocarditis recurrence with Enterococcus faecium","volume":"68","author":"Ortiz de la Rosa","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2025.12.004_bib34","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01520-17","article-title":"Genome-based analysis of Enterococcus faecium bacteremia associated with recurrent and mixed-strain infection","volume":"56","author":"Raven","year":"2018","journal-title":"J Clin Microbiol"},{"issue":"39","key":"10.1016\/j.idc.2025.12.004_bib35","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1093\/eurheartj\/ehz327","article-title":"Prevalence of infective endocarditis in patients with positive blood cultures: a Danish nationwide study","volume":"40","author":"Ostergaard","year":"2019","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.idc.2025.12.004_bib36","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.cmi.2020.10.029","article-title":"How do I manage a patient with enterococcal bacteraemia?","volume":"27","author":"Rosselli Del Turco","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.idc.2025.12.004_bib37","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00168-23","article-title":"The emerging challenge of Enterococcus faecalis endocarditis after transcatheter aortic valve implantation: time for innovative treatment approaches","volume":"37","author":"Cusumano","year":"2024","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"10.1016\/j.idc.2025.12.004_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0225077","article-title":"Infective endocarditis post-transcatheter aortic valve implantation (TAVI), microbiological profile and clinical outcomes: a systematic review","volume":"15","author":"Khan","year":"2020","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.idc.2025.12.004_bib39","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1093\/cid\/ciad431","article-title":"Patient characteristics, microbiology, and mortality of infective endocarditis after transcatheter aortic valve implantation","volume":"77","author":"Strange","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2025.12.004_bib40","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/cid\/ciu872","article-title":"The NOVA score: a proposal to reduce the need for transesophageal echocardiography in patients with enterococcal bacteremia","volume":"60","author":"Bouza","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2025.12.004_bib41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s15010-018-1208-3","article-title":"The DENOVA score efficiently identifies patients with monomicrobial Enterococcus faecalis bacteremia where echocardiography is not necessary","volume":"47","author":"Berge","year":"2019","journal-title":"Infection"},{"issue":"9","key":"10.1016\/j.idc.2025.12.004_bib42","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1128\/AAC.39.9.1984","article-title":"Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis","volume":"39","author":"Mainardi","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.idc.2025.12.004_bib43","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/cid\/cit052","article-title":"Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating enterococcus faecalis infective endocarditis","volume":"56","author":"Fernandez-Hidalgo","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2025.12.004_bib44","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jinf.2018.06.013","article-title":"Comparison of dual beta-lactam therapy to penicillin-aminoglycoside combination in treatment of Enterococcus faecalis infective endocarditis","volume":"77","author":"El Rafei","year":"2018","journal-title":"J Infect"},{"issue":"2","key":"10.1016\/j.idc.2025.12.004_bib45","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00361-18","article-title":"Structural and regulatory changes in PBP4 trigger decreased beta-lactam susceptibility in Enterococcus faecalis","volume":"9","author":"Rice","year":"2018","journal-title":"mBio"},{"issue":"487","key":"10.1016\/j.idc.2025.12.004_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat8418","article-title":"Impact of antibiotic treatment and host innate immune pressure on enterococcal adaptation in the human bloodstream","volume":"11","author":"Van Tyne","year":"2019","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.idc.2025.12.004_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nmicrobiol.2015.33","article-title":"Genome-based characterization of hospital-adapted Enterococcus faecalis lineages","volume":"1","author":"Raven","year":"2016","journal-title":"Nat Microbiol"},{"issue":"7","key":"10.1016\/j.idc.2025.12.004_bib48","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00291-19","article-title":"Prospective observational study of the clinical prognoses of patients with bloodstream infections caused by ampicillin-susceptible but penicillin-resistant Enterococcus faecalis","volume":"63","author":"Kim","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.idc.2025.12.004_bib49","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/jac\/dkae032","article-title":"Differential in vitro susceptibility to ampicillin\/ceftriaxone combination therapy among Enterococcus faecalis infective endocarditis clinical isolates","volume":"79","author":"Westbrook","year":"2024","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.idc.2025.12.004_bib50","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1093\/jac\/dkz173","article-title":"In vitro activity of ampicillin and ceftriaxone against ampicillin-susceptible Enterococcus faecium","volume":"74","author":"Lorenzo","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.idc.2025.12.004_bib51","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1093\/jac\/dkaf095","article-title":"Bactericidal activity of antibiotic combinations against clinical isolates of Enterococcus gallinarum and Enterococcus casseliflavus","volume":"80","author":"Landman","year":"2025","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"10.1016\/j.idc.2025.12.004_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/microorganisms12122511","article-title":"In vitro activity of ampicillin plus ceftriaxone against non-faecalis and non-faecium enterococcal isolates with\/without VanC phenotype: clinical implications for infective endocarditis","volume":"12","author":"Garcia-Gonzalez","year":"2024","journal-title":"Microorganisms"},{"issue":"10","key":"10.1016\/j.idc.2025.12.004_bib53","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1093\/jac\/dkaf226","article-title":"Is ampicillin plus cephalosporins a therapeutic option for ampicillin-susceptible enterococcus faecium?","volume":"80","author":"Bierge","year":"2025","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.idc.2025.12.004_bib54","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1038\/s41467-020-15257-1","article-title":"Ca(2+)-Daptomycin targets cell wall biosynthesis by forming a tripartite complex with undecaprenyl-coupled intermediates and membrane lipids","volume":"11","author":"Grein","year":"2020","journal-title":"Nat Commun"},{"issue":"45","key":"10.1016\/j.idc.2025.12.004_bib55","doi-asserted-by":"crossref","first-page":"E7077","DOI":"10.1073\/pnas.1611173113","article-title":"Daptomycin inhibits cell envelope synthesis by interfering with fluid membrane microdomains","volume":"113","author":"Muller","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.idc.2025.12.004_bib56","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1056\/NEJMoa1011138","article-title":"Genetic basis for in vivo daptomycin resistance in enterococci","volume":"365","author":"Arias","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.idc.2025.12.004_bib57","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/infdis\/jiae173","article-title":"Membrane lipids augment cell envelope stress signaling via the MadRS system to defend against antimicrobial peptides and antibiotics in Enterococcus faecalis","volume":"231","author":"Miller","year":"2025","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2025.12.004_bib58","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.1128\/AAC.02686-14","article-title":"Whole-genome analyses of Enterococcus faecium isolates with diverse daptomycin MICs","volume":"58","author":"Diaz","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.12.004_bib59","article-title":"Daptomycin resistance occurs predominantly in vanA-Type vancomycin-resistant Enterococcus faecium in Australasia and is associated with heterogeneous and novel mutations","volume":"12","author":"Li","year":"2021","journal-title":"Front Microbiol"},{"issue":"52","key":"10.1016\/j.idc.2025.12.004_bib60","doi-asserted-by":"crossref","first-page":"26925","DOI":"10.1073\/pnas.1916037116","article-title":"Antimicrobial sensing coupled with cell membrane remodeling mediates antibiotic resistance and virulence in Enterococcus faecalis","volume":"116","author":"Khan","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"22","key":"10.1016\/j.idc.2025.12.004_bib61","doi-asserted-by":"crossref","first-page":"e173836","DOI":"10.1172\/jci.insight.173836","article-title":"Molecular basis of cell membrane adaptation in daptomycin-resistant Enterococcus faecalis","volume":"9","author":"Nguyen","year":"2024","journal-title":"JCI Insight"},{"issue":"6","key":"10.1016\/j.idc.2025.12.004_bib62","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/mmi.15264","article-title":"Regulatory interactions between daptomycin- and bacitracin-responsive pathways coordinate the cell envelope antibiotic resistance response of Enterococcus faecalis","volume":"121","author":"Morris","year":"2024","journal-title":"Mol Microbiol"},{"issue":"8040","key":"10.1016\/j.idc.2025.12.004_bib63","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41586-024-08095-4","article-title":"Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin","volume":"635","author":"Turner","year":"2024","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.idc.2025.12.004_bib64","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1128\/AAC.00021-13","article-title":"A liaF codon deletion abolishes daptomycin bactericidal activity against vancomycin-resistant Enterococcus faecalis","volume":"57","author":"Munita","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.idc.2025.12.004_bib65","doi-asserted-by":"crossref","first-page":"5253","DOI":"10.1128\/AAC.00098-14","article-title":"Defining daptomycin resistance prevention exposures in vancomycin-resistant Enterococcus faecium and E. faecalis","volume":"58","author":"Werth","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.idc.2025.12.004_bib66","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1093\/cid\/ciy749","article-title":"Pharmacodynamic analysis of daptomycin-treated enterococcal bacteremia: it is time to change the breakpoint","volume":"68","author":"Avery","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2025.12.004_bib67","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/cid\/ciz845","article-title":"Development of daptomycin susceptibility breakpoints for Enterococcus faecium and revision of the breakpoints for other enterococcal species by the clinical and laboratory standards institute","volume":"70","author":"Satlin","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2025.12.004_bib68","doi-asserted-by":"crossref","first-page":"e00600","DOI":"10.1128\/JCM.00600-19","article-title":"The new, new daptomycin breakpoint for enterococcus spp","volume":"57","author":"Humphries","year":"2019","journal-title":"J Clin Microbiol"},{"issue":"8","key":"10.1016\/j.idc.2025.12.004_bib69","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.cmi.2020.04.027","article-title":"European Committee on Antimicrobial Susceptibility T. Daptomycin in the treatment of enterococcal bloodstream infections and endocarditis: a EUCAST position paper","volume":"26","author":"Turnidge","year":"2020","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.idc.2025.12.004_bib70","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab659","article-title":"Daptomycin-resistant enterococcus bacteremia is associated with prior daptomycin use and increased mortality after liver transplantation","volume":"9","author":"Lee","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2025.12.004_bib71","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jinf.2016.11.004","article-title":"Daptomycin non-susceptible Enterococcus faecium in leukemia patients: role of prior daptomycin exposure","volume":"74","author":"DiPippo","year":"2017","journal-title":"J Infect"},{"issue":"6","key":"10.1016\/j.idc.2025.12.004_bib72","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02294-22","article-title":"Remodeling of the enterococcal cell envelope during surface penetration promotes intrinsic resistance to stress","volume":"13","author":"Ramos","year":"2022","journal-title":"mBio"},{"issue":"4","key":"10.1016\/j.idc.2025.12.004_bib73","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijantimicag.2016.07.006","article-title":"Mutant prevention concentrations of daptomycin for Enterococcus faecium clinical isolates","volume":"48","author":"Sinel","year":"2016","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"10.1016\/j.idc.2025.12.004_bib74","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/cid\/ciw815","article-title":"Comparative effectiveness and safety of standard-medium-and high-dose daptomycin strategies for the treatment of vancomycin-resistant enterococcal bacteremia among veterans affairs patients","volume":"64","author":"Britt","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2025.12.004_bib75","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/cid\/cix024","article-title":"Effect of daptomycin dose on the outcome of vancomycin-Resistant, Daptomycin-Susceptible Enterococcus faecium bacteremia","volume":"64","author":"Chuang","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2025.12.004_bib76","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/jac\/dkac164","article-title":"Influence of daptomycin doses on the outcomes of VRE bloodstream infection treated with high-dose daptomycin","volume":"77","author":"Chuang","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.idc.2025.12.004_bib77","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1128\/AAC.00053-15","article-title":"beta-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic\/pharmacodynamic models","volume":"59","author":"Smith","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.idc.2025.12.004_bib78","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1093\/infdis\/jiaa319","article-title":"Mechanistic insights into the differential efficacy of Daptomycin plus beta-Lactam combinations against Daptomycin-Resistant Enterococcus faecium","volume":"222","author":"Kebriaei","year":"2020","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.idc.2025.12.004_bib79","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.jiph.2022.10.017","article-title":"The combination of daptomycin with beta-lactam antibiotics is more effective than daptomycin alone for vancomycin-resistant Enterococcus faecium bloodstream infection","volume":"15","author":"Chuang","year":"2022","journal-title":"J Infect Public Health"},{"issue":"3","key":"10.1016\/j.idc.2025.12.004_bib80","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1128\/AAC.02099-12","article-title":"Fosfomycin synergy in vitro with amoxicillin, daptomycin, and linezolid against vancomycin-resistant Enterococcus faecium from renal transplant patients with infected urinary stents","volume":"57","author":"Descourouez","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2025.12.004_bib81","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/jac\/dkac023","article-title":"Influence of daptomycin dose and fosfomycin susceptibility on outcome of vancomycin-resistant Enterococcus faecium bloodstream infections treated with daptomycin and fosfomycin combination","volume":"77","author":"Chuang","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.idc.2025.12.004_bib82","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40121-022-00754-1","article-title":"The combination of Daptomycin with Fosfomycin is more effective than Daptomycin alone in reducing mortality of vancomycin-resistant enterococcal bloodstream infections: a retrospective, comparative cohort Study","volume":"12","author":"Tseng","year":"2023","journal-title":"Infect Dis Ther"},{"issue":"3","key":"10.1016\/j.idc.2025.12.004_bib83","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2007.04.005","article-title":"The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria","volume":"26","author":"Leach","year":"2007","journal-title":"Mol Cell"},{"key":"10.1016\/j.idc.2025.12.004_bib84","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.drup.2018.10.002","article-title":"Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: towards a common nomenclature","volume":"40","author":"Bender","year":"2018","journal-title":"Drug Resist Updat"},{"issue":"10","key":"10.1016\/j.idc.2025.12.004_bib85","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1128\/AAC.46.10.3334-3336.2002","article-title":"Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis","volume":"46","author":"Marshall","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2025.12.004_bib86","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/s41467-022-29274-9","article-title":"Structural basis for PoxtA-mediated resistance to phenicol and oxazolidinone antibiotics","volume":"13","author":"Crowe-McAuliffe","year":"2022","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.idc.2025.12.004_bib87","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1261\/rna.1371409","article-title":"Identification of 8-methyladenosine as the modification catalyzed by the radical SAM methyltransferase Cfr that confers antibiotic resistance in bacteria","volume":"15","author":"Giessing","year":"2009","journal-title":"RNA"},{"issue":"4","key":"10.1016\/j.idc.2025.12.004_bib88","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s10096-024-04784-0","article-title":"Risk factors and outcome associated with the acquisition of MDR linezolid-resistant enterococcus faecium: a report from tertiary care centre","volume":"43","author":"Rani","year":"2024","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2025.12.004_bib89","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00228-020-02990-1","article-title":"Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic\/pharmacodynamic analysis","volume":"77","author":"Gatti","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.idc.2025.12.004_bib90","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3947\/ic.2021.0034","article-title":"Optimization of linezolid dosing regimens for treatment of vancomycin-resistant enterococci infection","volume":"53","author":"Santimaleeworagun","year":"2021","journal-title":"Infect Chemother"},{"issue":"10","key":"10.1016\/j.idc.2025.12.004_bib91","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1128\/AAC.00714-13","article-title":"Systematic review and meta-analysis of linezolid and daptomycin for treatment of vancomycin-resistant enterococcal bloodstream infections","volume":"57","author":"Whang","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2025.12.004_bib92","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01289-13","article-title":"Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia","volume":"58","author":"Balli","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.12.004_bib93","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1186\/s12879-014-0687-9","article-title":"Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis","volume":"14","author":"Chuang","year":"2014","journal-title":"BMC Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2025.12.004_bib94","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/cid\/civ444","article-title":"Comparison of the effectiveness and safety of linezolid and daptomycin in vancomycin-resistant enterococcal bloodstream infection: a national cohort study of veterans affairs patients","volume":"61","author":"Britt","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2025.12.004_bib95","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02216-16","article-title":"Effect of continuous and sequential therapy among veterans receiving daptomycin or linezolid for vancomycin-resistant Enterococcus faecium bacteremia","volume":"61","author":"Britt","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"25","key":"10.1016\/j.idc.2025.12.004_bib96","first-page":"00153","article-title":"High-dose daptomycin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bloodstream infections: role of pharmacodynamic target attainment","volume":"S1684-1182","author":"Hwang","year":"2025","journal-title":"J Microbiol Immunol Infect"},{"issue":"10","key":"10.1016\/j.idc.2025.12.004_bib97","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1586\/14787210.2014.956092","article-title":"Mechanisms of antibiotic resistance in enterococci","volume":"12","author":"Miller","year":"2014","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"6","key":"10.1016\/j.idc.2025.12.004_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106215","article-title":"In vitro activity of eravacycline and mechanisms of resistance in enterococci","volume":"56","author":"Boukthir","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"12","key":"10.1016\/j.idc.2025.12.004_bib99","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01314-25","article-title":"Combating resistant pathogens: exploring the efficacy of eravacycline utilization in multidrug-resistant infections","volume":"13","author":"Patino","year":"2025","journal-title":"Microbiol Spectr"},{"issue":"12","key":"10.1016\/j.idc.2025.12.004_bib100","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1345\/aph.1M324","article-title":"Multidrug-resistant Enterococcus faecium endocarditis treated with combination tigecycline and high-dose daptomycin","volume":"43","author":"Schutt","year":"2009","journal-title":"Ann Pharmacother"},{"issue":"Suppl 3","key":"10.1016\/j.idc.2025.12.004_bib101","doi-asserted-by":"crossref","first-page":"S214","DOI":"10.1093\/cid\/cir920","article-title":"Oritavancin: mechanism of action","volume":"54","author":"Zhanel","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2025.12.004_bib102","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01667-21","article-title":"Activity of oritavancin against gram-positive pathogens causing bloodstream infections in the United States over 10 years: focus on drug-resistant enterococcal subsets (2010-2019)","volume":"66","author":"Carvalhaes","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2025.12.004_bib103","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12879-023-08725-8","article-title":"Oritavancin as sequential therapy for Gram-positive bloodstream infections","volume":"24","author":"Texidor","year":"2024","journal-title":"BMC Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2025.12.004_bib104","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.cmi.2024.01.008","article-title":"Successful treatment of complicated infective endocarditis due to Enterococcus faecium in a patient with substance use disorder using oritavancin as sequential maintenance therapy","volume":"30","author":"Giuliano","year":"2024","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"10.1016\/j.idc.2025.12.004_bib105","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1097\/CORR.0000000000003449","article-title":"Can oritavancin be used for treatment and\/or suppressive antimicrobial therapy of bone and joint infections caused by vancomycin-resistant Enterococcus faecium","volume":"483","author":"Krsak","year":"2025","journal-title":"Clin Orthop Relat Res"},{"issue":"12","key":"10.1016\/j.idc.2025.12.004_bib106","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3390\/antibiotics13121120","article-title":"Bacteriophage therapy as a promising alternative for antibiotic-resistant enterococcus faecium: advances and challenges","volume":"13","author":"Ribes-Martinez","year":"2024","journal-title":"Antibiotics (Basel)"},{"issue":"3","key":"10.1016\/j.idc.2025.12.004_bib107","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02071-21","article-title":"Considerations for the use of phage therapy in clinical practice","volume":"66","author":"Suh","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2025.12.004_bib108","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.03396-23","article-title":"Bacteriophage and antibiotic combination therapy for recurrent Enterococcus faecium bacteremia","volume":"15","author":"Stellfox","year":"2024","journal-title":"mBio"},{"issue":"5","key":"10.1016\/j.idc.2025.12.004_bib109","first-page":"252","article-title":"Bacteriophage therapy for critical infections related to cardiothoracic surgery","volume":"9","author":"Rubalskii","year":"2020","journal-title":"Antibiotics (Basel)"},{"issue":"11","key":"10.1016\/j.idc.2025.12.004_bib110","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.3390\/cells9112397","article-title":"Advances and prospects in vaccine development against enterococci","volume":"9","author":"Kalfopoulou","year":"2020","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.idc.2025.12.004_bib111","doi-asserted-by":"crossref","first-page":"e01653","DOI":"10.1128\/mBio.01653-16","article-title":"Antibody-Based therapy for enterococcal catheter-associated urinary tract infections","volume":"7","author":"Flores-Mireles","year":"2016","journal-title":"mBio"},{"issue":"12","key":"10.1016\/j.idc.2025.12.004_bib112","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/cid\/ciy378","article-title":"Difficult-to-Treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.idc.2025.12.004_bib113","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01060-24","article-title":"Therapeutic approach to difficult-to-treat multidrug-resistant enterococcal infections","volume":"69","author":"Turner","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.idc.2025.12.004_bib114","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1128\/AAC.03006-15","article-title":"Oritavancin combinations with beta-Lactams against multidrug-resistant Staphylococcus aureus and vancomycin-resistant enterococci","volume":"60","author":"Smith","year":"2016","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552025001096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552025001096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T20:42:43Z","timestamp":1773780163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552025001096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":114,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0891552025001096"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2025.12.004","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Management of Serious Infections due to Vancomycin-resistant Enterococci","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2025.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}